News

AstraZeneca and Ardea Biosciences, Inc. have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea's clinically most advanced product candidate, lesinurad...

A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate the transfer of information between nerve cells in the brain. The discovery, made by...

Rosetta Genomics has won a European patent covering the use of miR-34a in the preparation of pharmaceuticals used to treat p53-negative cancers. The patent covers a core element of Rosetta's microRNA technology in the...

Women with acute coronary syndrome (ACS) receive inferior or less aggressive treatment compared to men, according to three large studies presented today at the World Congress of Cardiology. The CREATE registry study of 20,468...

  Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. "A major...

Abbott has announced the Phase 3 study results of its levodopa-carbidopa intestinal gel (LCIG), used for the treatment of advanced Parkinson's Disease (PD). LCIG is administered via a procedurally-implanted tube connected to a portable...

VistaGen Therapeutics has signed a licensing agreement with the McEwen Centre for Regenerative Medicine located at the University Health Network in Toronto, Canada, for stem cell culture technology. VistaGen will utilize the licensed technology...